Vanderbilt Center for Antibody Therapeutics signs agreement to develop anti-measles antibody treatment
The Vanderbilt Center for Antibody Therapeutics has signed an option agreement with Saravir Biopharma Inc. for the company to develop human monoclonal antibodies isolated in the laboratory of James Crowe Jr., MD, for the treatment and prevention of measles.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.